Trade Incyte Corporation - INCY CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.15 | ||||||||
|
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.024124% | ||||||||
|
Short position overnight fee
Short position overnight funding adjustment
Go to platform | 0.001901% | ||||||||
| Overnight fee time | 22:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | USD | ||||||||
| Margin | 5.00% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
| Prev. Close | 70.95 |
| Open | 70.4 |
| 1-Year Change | 28.87% |
| Day's Range | 69.48 - 71.15 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Nov 20, 2024 | 70.95 | 0.77 | 1.10% | 70.18 | 71.57 | 69.95 |
| Nov 19, 2024 | 70.48 | 3.95 | 5.94% | 66.53 | 73.69 | 64.97 |
| Nov 18, 2024 | 76.70 | 1.20 | 1.59% | 75.50 | 76.95 | 74.72 |
| Nov 15, 2024 | 75.82 | -1.26 | -1.63% | 77.08 | 77.74 | 73.11 |
| Nov 14, 2024 | 77.62 | -2.01 | -2.52% | 79.63 | 80.26 | 77.34 |
| Nov 13, 2024 | 80.38 | 0.35 | 0.44% | 80.03 | 81.56 | 80.03 |
| Nov 12, 2024 | 80.53 | -0.51 | -0.63% | 81.04 | 81.85 | 80.14 |
| Nov 11, 2024 | 81.45 | -1.64 | -1.97% | 83.09 | 83.34 | 80.99 |
| Nov 8, 2024 | 83.33 | 1.36 | 1.66% | 81.97 | 83.88 | 81.85 |
| Nov 7, 2024 | 82.24 | 2.00 | 2.49% | 80.24 | 82.53 | 79.28 |
| Nov 6, 2024 | 80.85 | 2.69 | 3.44% | 78.16 | 82.03 | 78.03 |
| Nov 5, 2024 | 77.19 | 2.08 | 2.77% | 75.11 | 77.31 | 74.94 |
| Nov 4, 2024 | 75.67 | 0.64 | 0.85% | 75.03 | 76.47 | 74.83 |
| Nov 1, 2024 | 76.06 | 3.11 | 4.26% | 72.95 | 76.27 | 72.95 |
| Oct 31, 2024 | 74.05 | 1.00 | 1.37% | 73.05 | 74.59 | 72.87 |
| Oct 30, 2024 | 73.85 | 0.94 | 1.29% | 72.91 | 74.26 | 72.18 |
| Oct 29, 2024 | 73.27 | 7.05 | 10.65% | 66.22 | 73.96 | 66.22 |
| Oct 28, 2024 | 65.63 | 0.89 | 1.37% | 64.74 | 65.82 | 64.71 |
| Oct 25, 2024 | 65.00 | -0.02 | -0.03% | 65.02 | 65.66 | 64.76 |
| Oct 24, 2024 | 65.19 | 0.43 | 0.66% | 64.76 | 65.82 | 64.76 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
Incyte Company profile
About Incyte Corporation
Incyte Corporation is a biopharmaceutical company, which is focused on the discovery, development and commercialization of therapeutics. The Company also conducts commercial and clinical development operations from its European headquarters in Morges, Switzerland and Japanese office in Tokyo. It operates in two therapeutic areas, One therapeutic area is Hematology/Oncology, which is comprised of Myeloproliferative Neoplasms and Graft-Versus-Host Disease, as well as solid tumors and hematologic malignancies. The other therapeutic area is Inflammation and Autoimmunity, which includes its Dermatology commercial franchise. Its hematology and oncology franchise is comprised of four products, which are JAKAFI (ruxolitinib), MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab), PEMAZYRE (pemigatinib) and ICLUSIG (ponatinib), as well as other clinical development programs. Its Dermatology commercial franchise is comprised of OPZELURA (ruxolitinib) cream and other clinical development programs.
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, Incyte Corporation revenues increased 12% to $2.99B. Net income totaled $948.6M vs. loss of $295.7M. Revenues reflect JAKAFI revenues segment increase of 10% to $2.13B, OLUMIANT product royalty revenues segment increase of 99% to $220.9M. Net Income reflects Other Research and development decrease of 47% to $902.3M (expense), Change in fair value of acquisition-rela decrease of 37% to $14.7M (expense).
Equity composition
Common Stock $.001 Par, 04/11, 400M auth.,124,585,982. issd. Insiders & stakeholders own 1.22%. IPO: 11/93, 2M shares @ $7.50by D. Blech and Co. PO 11/95, 1.7M shares @ $19 by Hambrecht & Quist. PO 9/97, 1.38M shs @ $67 by Hambrecht & Quist. 9/00, 11/97, 2-for-1 stock splits. 6/00, Name chgd. from Incyte Pharmaceuticals, Inc. PO:10.5M shares
| Industry: | Biopharmaceuticals |
1801 Augustine Cut-Off
WILMINGTON
DELAWARE 19803
US
News
Gold price predictions for the next five years: Third party data round up
Explore the future of gold prices and whether the yellow metal will continue its upward trend in the coming years.
15:17, 18 November 2024
Shiba Inu coin price prediction 2030: could Shiba Inu coin reach $1? Third party price target
Can Shiba Inu reinvent itself to become a worthy long-term investment?
08:36, 15 November 2024
Trump trades charge as Bitcoin hits $US80,000
Bitcoin hits $80,000 amid expectations of fiscal stimulus, lower regulatory risks, and resilient US economy.
10:48, 13 November 2024
Australian jobs data expected to point to solid labour market conditions
Australian labour market and wage data to reveal job growth resilience, shaping RBA rate cut expectations and impacting AUD amidst global economic shifts.
10:16, 13 November 2024
FOMC cuts interest rates as expected and sticks to its line on future policy
The FOMC cut interest rates by 25 basis points at its November meeting, aligning with expectations. Wall Street hit record highs following the decision, with tech stocks leading the rally. Markets are pricing in a probable December cut amid resilient economic indicators.
13:33, 8 November 2024
FOMC and BOE preview: further rate cuts expected
Both the Federal Reserve and the Bank of England are expected to cut rates further when they meet later this week.
14:14, 5 November 2024
RBA meeting preview: No change to policy expected as inflation fight continues
The Reserve Bank of Australia is expected to keep its cash rate on hold at 4.35% when it announces its policy decision at 2.30PM on the 5th of November, 2024. Despite ongoing evidence of soft demand, upside risks to inflation are likely to remain the central bank’s primary concern.
13:35, 4 November 2024People also watch
Still looking for a broker you can trust?
Join the 660,000+ traders worldwide that chose to trade with Capital.com